The recently updated Osteoarthritis Research Society International (OARSI) guideline offers comprehensive and patient-centered treatment approaches for individuals with knee, hip and polyarticular OA…
RheumPAC Advocates for Dept. of Defense Arthritis Research Funding
RheumPAC is the ACR’s non-partisan political action committee, which promotes the needs of rheumatology providers and patients. Advocacy efforts often focus on legislation to improve the day-to-day clinical care of rheumatology patients, such as establishing clinical exceptions to step therapy requirements and reforming the prior authorization process. In addition, the ACR and RheumPAC recognize the…
If It’s Broken, Fix It: Can an Automated System Predict Short-Term Fracture Risk?
A clinician’s ability to determine which patients are at greatest risk for hip or other fracture is improving with the use of algorithm-based fracture risk calculators…
High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…
No Gain with Pain: Exercise & Physical Function in Patients with Rheumatic Disease
Pain can deter patients with rheumatic disease from engaging in physical activity. But the latest research shows exercise helps reduce pain, & other influences may also affect patients’ activity levels, particularly after surgery…
Osteoporosis Drugs Don’t Reduce Overall Mortality
NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis. “This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA…
ACR Volunteer Leaders Visit Capitol Hill, Lobby for 5 Issues
WASHINGTON, D.C.—Dozens of rheumatology leaders met with more than 100 politicos on Capitol Hill in mid-May as part of the ACR’s annual Advocacy Leadership Conference. Armed with research and advocacy training concerning a handful of important issues, rheumatologists, rheumatology interprofessional team members, government affairs specialists and others met with federal lawmakers, legislative aides and correspondents….
Exercise Therapy Benefits Patients with Knee & Hip OA
A meta-analysis confirms prior research suggesting exercise therapy benefits patients with knee and hip osteoarthritis (OA). The study found greater improvements in pain, function, performance and quality of life in patients with milder, as opposed to more severe, OA…
Diet & Exercise: What’s the Economic Benefit for Overweight & Obese Patients with Knee OA?
New research recently found that, when combined with standard treatment, diet and exercise regimens are cost effective for overweight and obese patients with knee OA…
U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug
WASHINGTON (Reuters)—On May 20, the U.S. Supreme Court threw out a lower court ruling that had revived hundreds of lawsuits accusing Merck & Co. of failing to properly warn patients of debilitating thigh-bone fractures as a result of taking its osteoporosis drug alendronic acid (Fosamax). The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 46
- Next Page »